ICPT up +3.56% percent Today $ICPT High is at 182.00 and the Low 172.60 with current volume of 650,406.
Recent News posted below.
Intercept Pharmaceuticals Inc ICPT other info.
http://investorshangout.com/Intercept-Pharmac...CPT-90145/
ICPT Intercept Pharmaceuticals Inc Recent Headline News
Global Chronic Kidney Disease (Chronic Renal Failure) Therapeutics Pipeline Report H2 2014 - Analysis of 27 Companies & 39 Drug Profiles
M2 - 35 mins ago
Research and Markets (http://www.researchandmarkets.com/research/n5l8s3/chronic_kidney) has announced the addition of the "Chronic Kidney Disease (Chronic Renal Failure) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Chronic Kidney Disease (Chronic Renal Failure), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Kidney Disease (Chronic Renal Failure) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Hospira, Inc. - AstraZeneca PLC - Eli Lilly and Company - Quark Pharmaceuticals, Inc. - Astellas Pharma Inc. - OPKO Health, Inc. - Toray Industries, Inc. - Evotec AG - NPS Pharmaceuticals, Inc. - La Jolla Pharmaceutical Company - Alexion Pharmaceuticals, Inc. - AFFiRiS AG - Acceleron Pharma, Inc. - Nippon Zoki Pharmaceutical Co., Ltd. - Catabasis Pharmaceuticals, Inc. - Angion Biomedica Corp. - Concert Pharmaceuticals, Inc. - Intercept Pharmaceuticals, Inc. - Vitae Pharmaceuticals, Inc. - TRACON Pharmaceuticals, Inc. - Stelic Institute & Co. - Vicore Pharma AB - Otsuka Holdings Co., Ltd. - Sphaera Pharma Pvt. Ltd. - Multi Gene Vascular Systems Ltd - Bio-inRen - Red Glead Discovery AB For more information visit http://www.researchandmarkets.com/research/n5...nic_kidney
VTAE: 16.25 (+1.81), LLY: 67.85 (+1.25), CNCE: 13.48 (+0.38), OPK: 8.57 (+0.25), AZN: 73.29 (+0.41), ALXN: 194.76 (+0.95), ICPT: 177.70 (+5.11), NPSP: 26.97 (-0.52), XLRN: 31.94 (+1.75)
Intercept Pharmaceuticals (ICPT) Marked As A Dead Cat Bounce Stock
at The Street - 2 hrs 19 mins ago
Trade-Ideas LLC identified Intercept Pharmaceuticals (ICPT) as a "dead cat bounce" (down big yesterday but up big today) candidate
ICPT: 177.70 (+5.11)
Intercept Announces Additional Data for OCA in Primary Biliary Cirrhosis
GlobeNewswire - Sat Nov 08, 7:01AM CST
Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT) (Intercept), a clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat chronic liver and intestinal diseases, announced today new analyses of data from clinical trials on obeticholic acid (OCA) in patients with primary biliary cirrhosis (PBC). Six posters, including posters with new analyses of data from POISE - the first Phase 3 trial in PBC in two decades - are being presented at today's poster session at the American Association for the Study of Liver Disease (AASLD) Annual Meeting.
ICPT: 177.70 (+5.11)
Nasdaq stocks posting largest percentage decreases
AP - Fri Nov 07, 5:08PM CST
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
TNGO: 12.29 (+0.05), PRSC: 38.07 (-0.41), FNGN: 31.05 (-0.34), LACO: 6.92 (+0.01), MSON: 11.34 (-0.46), SLXP: 93.43 (+1.96), FNHC: 26.43 (+0.29), MDRX: 11.45 (-0.09), PCMI: 8.59 (+1.14), UBNT: 29.42 (+0.64), PFMT: 6.62 (-0.42), ICPT: 177.70 (+5.11), ANDE: 53.91 (-0.88), ACTA: 16.68 (+0.16)
Stock Movers: Why These 4 Medical Stocks Dived Today
at Investor's Business Daily - Fri Nov 07, 3:36PM CST
Raised eyebrows can lead to declining stock prices. Stocks On The Move down today include Salix Pharmaceuticals (SLXP), embroiled in drama as questions of accuracy and honesty cloud the drugmaker's weak Q3 results. Are its inventories accurate, and...
AGN: 196.61 (+0.61), VRX: 127.58 (+1.47), DVA: 74.52 (+0.03), GILD: 108.23 (+1.78), SLXP: 93.43 (+1.96), ICPT: 177.70 (+5.11), HUM: 132.95 (+2.37)
Why Intercept Pharmaceuticals Inc. Stock Was Decimated
Sean Williams, The Motley Fool - Motley Fool - Fri Nov 07, 2:32PM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Intercept Pharmaceuticals , a...
ICPT: 177.70 (+5.11)
Global Alcoholic Hepatitis Therapeutics Pipeline Review 2014 - 5 Companies & 6 Drug Profiles
M2 - Fri Nov 07, 5:32AM CST
Research and Markets (http://www.researchandmarkets.com/research/6xxsjw/alcoholic) has announced the addition of the "Alcoholic Hepatitis - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Alcoholic Hepatitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Alcoholic Hepatitis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Immuron Limited - Conatus Pharmaceuticals Inc. - Intercept Pharmaceuticals, Inc. - Alfact Innovation - Generon (Shanghai) Corporation Ltd. Drug Profiles - obeticholic acid - emricasan - IMM-124E - ALF-5755 - F-652 - Oligonucleotide to Inhibit miRNA-155 for Alcoholic Liver Disease For more information visit http://www.researchandmarkets.com/research/6xxsjw/alcoholic
CNAT: 7.01 (+0.16), ICPT: 177.70 (+5.11)
Intercept misses 3Q profit forecasts
Automated Insights - Fri Nov 07, 4:04AM CST
NEW YORK (AP) _ Intercept Pharmaceuticals Inc. (ICPT) on Friday reported a third-quarter loss of $35.8 million.
ICPT: 177.70 (+5.11)
FLINT Trial in NASH Published in The Lancet
GlobeNewswire - Thu Nov 06, 6:05PM CST
-OCA meets primary endpoint with high statistical significance of p=0.0002
ICPT: 177.70 (+5.11)
Intercept Pharmaceuticals Reports Third Quarter 2014 Financial Results and Provides Business Updates
GlobeNewswire - Thu Nov 06, 4:28PM CST
Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT) (Intercept), a clinical stage biopharmaceutical company focused on the development and commercialization of novel bile acid therapeutics to treat chronic liver and intestinal diseases, today reported financial results for the quarter and nine months ended September 30, 2014 and provided other general business updates. These results are included in Intercept's Quarterly Report on Form 10-Q which has been filed with the Securities and Exchange Commission. Intercept will webcast an investor event on Monday, November 10, 2014 starting at 6:30 p.m. ET. During this webcast, management and key opinion leaders will review Intercept's development programs, including PBC and NASH.
ICPT: 177.70 (+5.11)
Will Intercept Pharmaceuticals' (ICPT) Q3 Loss Narrow? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 06, 3:02PM CST
Intercept Pharmaceuticals, Inc (ICPT) is slated to report its third-quarter 2014 results on Nov 7.
MACK: 8.63 (-0.07), MNK: 92.65 (+1.59), DNDN: 0.23 (-0.71), ICPT: 177.70 (+5.11)
Intercept to Report Third Quarter 2014 Results on November 7 and Present at Upcoming Conferences
GlobeNewswire - Fri Oct 31, 5:01AM CDT
Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT) (Intercept), a clinical stage biopharmaceutical company focused on the development and commercialization of novel bile acid therapeutics to treat chronic liver and intestinal diseases, today announced that it will report third quarter 2014 financial results before the NASDAQ Market opens on Friday, November 7, 2014. Intercept will webcast an investor event on Monday, November 10, 2014 starting at 6:30 p.m. ET. During this webcast, management and key opinion leaders will review Intercept's development programs, including its programs for PBC and NASH.
ICPT: 177.70 (+5.11)
Recognition, Product Enhancement, Marketing Approval, Upcoming Events, and Quarterly Earnings - Research Reports on Abbott, Illumina, Thermo Fisher, Intercept and Stryker
PR Newswire - Wed Oct 22, 7:40AM CDT
Today, Analysts Review released its research reports regarding Abbott Laboratories (NYSE: ABT), Illumina Inc. (NASDAQ: ILMN), Thermo Fisher Scientific, Inc. (NYSE: TMO), Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT) and Stryker Corporation (NYSE: SYK). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7389-100free.
ABT: 43.71 (+0.34), TMO: 117.06 (+0.46), ICPT: 177.70 (+5.11), ILMN: 189.51 (+3.16), SYK: 88.17 (+0.70)
Critical Alerts For Exxon Mobil, Celgene, Verizon, Intercept Pharmaceuticals and Lockheed Martin Released By InvestorsObserver
PR Newswire - Wed Oct 08, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for XOM, CELG, VZ, ICPT and LMT.
LMT: 186.92 (+0.77), ICPT: 177.70 (+5.11), XOM: 96.47 (-0.12), VZ: 50.96 (+0.10), CELG: 107.90 (+1.45)
Intercept Announces Data to be Presented at the 2014 AASLD Annual Meeting
GlobeNewswire - Wed Oct 08, 5:36AM CDT
Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat chronic liver and intestinal diseases, today announced upcoming presentations of data at the upcoming American Academy for the Study of Liver Diseases (AASLD) Annual Meeting (the Liver Meeting), being held in Boston, Massachusetts from November 7-11, 2014.
ICPT: 177.70 (+5.11)
The 5 Best Biotech Stocks in 2014...so far
Todd Campbell, The Motley Fool - Motley Fool - Fri Sep 26, 7:35AM CDT
Since the quarter is wrapping up and investors are considering their game plan heading into year-end, let's look at biotech's biggest winners for the year, why they've rallied, and whether they make sense for your portfolio . Specifically, let's...
GILD: 108.23 (+1.78), ACHN: 12.37 (+2.26), RCPT: 110.10 (+0.86), PTCT: 40.99 (+0.75), ICPT: 177.70 (+5.11), PBYI: 241.09 (+4.20)
Quarterly Changes to the NASDAQ Q-50 Index
GlobeNewswire - Mon Sep 15, 6:08AM CDT
The NASDAQ OMX Group, Inc. (Nasdaq:NDAQ) today announced the results of the quarterly re-ranking of the NASDAQ Q-50 Index (Nasdaq:NXTQ), which will become effective prior to market open on Monday, September 22, 2014.
FLEX: 10.85 (-0.01), GLNG: 51.77 (+0.74), NTES: 92.60 (+0.80), FEYE: 31.95 (+1.33), NUAN: 15.38 (+0.06), GPOR: 53.77 (-1.39), MDVN: 110.12 (-2.65), FOSL: 103.67 (+0.66), SCTY: 51.64 (+0.67), ARMH: 41.97 (+0.53), ICPT: 177.70 (+5.11), SPLK: 66.71 (-0.16), NDAQ: 43.98 (+0.10)
Intercept Pharmaceuticals Recognizes International PBC Day
GlobeNewswire - Fri Sep 12, 5:55AM CDT
Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat chronic liver and intestinal diseases, announced today its support for International Primary Biliary Cirrhosis (PBC) Day, taking place September 14, 2014.
ICPT: 177.70 (+5.11)
Global Cirrhosis Therapeutics Pipeline Review 2014 - 7 Companies & 8 Drug Profiles
M2 - Fri Sep 12, 4:03AM CDT
Research and Markets (http://www.researchandmarkets.com/research/szkbdq/cirrhosis) has announced the addition of the "Cirrhosis - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Cirrhosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cirrhosis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Gilead Sciences, Inc. - Novartis AG - Ocera Therapeutics, Inc. - Hyperion Therapeutics, Inc. - Intercept Pharmaceuticals, Inc. - PharmaIN Corporation - Alfact Innovation Drug Profiles - ornithine phenylacetate - glycerol phenylbutyrate - obeticholic acid - simtuzumab - Stem Cell Therapy for Gastrointestinal, CNS and Endocrine and Metabolic Disorders - erismodegib - ALF-5755 - PGC Based Natriuretic Peptides For more information visit http://www.researchandmarkets.com/research/szkbdq/cirrhosis
GILD: 108.23 (+1.78), OCRX: 5.65 (+0.04), ICPT: 177.70 (+5.11), NVS: 92.58 (+0.82), HPTX: 21.71 (-0.11)
Recent News posted below.
Intercept Pharmaceuticals Inc ICPT other info.
http://investorshangout.com/Intercept-Pharmac...CPT-90145/
ICPT Intercept Pharmaceuticals Inc Recent Headline News
Global Chronic Kidney Disease (Chronic Renal Failure) Therapeutics Pipeline Report H2 2014 - Analysis of 27 Companies & 39 Drug Profiles
M2 - 35 mins ago
Research and Markets (http://www.researchandmarkets.com/research/n5l8s3/chronic_kidney) has announced the addition of the "Chronic Kidney Disease (Chronic Renal Failure) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Chronic Kidney Disease (Chronic Renal Failure), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Kidney Disease (Chronic Renal Failure) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Hospira, Inc. - AstraZeneca PLC - Eli Lilly and Company - Quark Pharmaceuticals, Inc. - Astellas Pharma Inc. - OPKO Health, Inc. - Toray Industries, Inc. - Evotec AG - NPS Pharmaceuticals, Inc. - La Jolla Pharmaceutical Company - Alexion Pharmaceuticals, Inc. - AFFiRiS AG - Acceleron Pharma, Inc. - Nippon Zoki Pharmaceutical Co., Ltd. - Catabasis Pharmaceuticals, Inc. - Angion Biomedica Corp. - Concert Pharmaceuticals, Inc. - Intercept Pharmaceuticals, Inc. - Vitae Pharmaceuticals, Inc. - TRACON Pharmaceuticals, Inc. - Stelic Institute & Co. - Vicore Pharma AB - Otsuka Holdings Co., Ltd. - Sphaera Pharma Pvt. Ltd. - Multi Gene Vascular Systems Ltd - Bio-inRen - Red Glead Discovery AB For more information visit http://www.researchandmarkets.com/research/n5...nic_kidney
VTAE: 16.25 (+1.81), LLY: 67.85 (+1.25), CNCE: 13.48 (+0.38), OPK: 8.57 (+0.25), AZN: 73.29 (+0.41), ALXN: 194.76 (+0.95), ICPT: 177.70 (+5.11), NPSP: 26.97 (-0.52), XLRN: 31.94 (+1.75)
Intercept Pharmaceuticals (ICPT) Marked As A Dead Cat Bounce Stock
at The Street - 2 hrs 19 mins ago
Trade-Ideas LLC identified Intercept Pharmaceuticals (ICPT) as a "dead cat bounce" (down big yesterday but up big today) candidate
ICPT: 177.70 (+5.11)
Intercept Announces Additional Data for OCA in Primary Biliary Cirrhosis
GlobeNewswire - Sat Nov 08, 7:01AM CST
Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT) (Intercept), a clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat chronic liver and intestinal diseases, announced today new analyses of data from clinical trials on obeticholic acid (OCA) in patients with primary biliary cirrhosis (PBC). Six posters, including posters with new analyses of data from POISE - the first Phase 3 trial in PBC in two decades - are being presented at today's poster session at the American Association for the Study of Liver Disease (AASLD) Annual Meeting.
ICPT: 177.70 (+5.11)
Nasdaq stocks posting largest percentage decreases
AP - Fri Nov 07, 5:08PM CST
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
TNGO: 12.29 (+0.05), PRSC: 38.07 (-0.41), FNGN: 31.05 (-0.34), LACO: 6.92 (+0.01), MSON: 11.34 (-0.46), SLXP: 93.43 (+1.96), FNHC: 26.43 (+0.29), MDRX: 11.45 (-0.09), PCMI: 8.59 (+1.14), UBNT: 29.42 (+0.64), PFMT: 6.62 (-0.42), ICPT: 177.70 (+5.11), ANDE: 53.91 (-0.88), ACTA: 16.68 (+0.16)
Stock Movers: Why These 4 Medical Stocks Dived Today
at Investor's Business Daily - Fri Nov 07, 3:36PM CST
Raised eyebrows can lead to declining stock prices. Stocks On The Move down today include Salix Pharmaceuticals (SLXP), embroiled in drama as questions of accuracy and honesty cloud the drugmaker's weak Q3 results. Are its inventories accurate, and...
AGN: 196.61 (+0.61), VRX: 127.58 (+1.47), DVA: 74.52 (+0.03), GILD: 108.23 (+1.78), SLXP: 93.43 (+1.96), ICPT: 177.70 (+5.11), HUM: 132.95 (+2.37)
Why Intercept Pharmaceuticals Inc. Stock Was Decimated
Sean Williams, The Motley Fool - Motley Fool - Fri Nov 07, 2:32PM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Intercept Pharmaceuticals , a...
ICPT: 177.70 (+5.11)
Global Alcoholic Hepatitis Therapeutics Pipeline Review 2014 - 5 Companies & 6 Drug Profiles
M2 - Fri Nov 07, 5:32AM CST
Research and Markets (http://www.researchandmarkets.com/research/6xxsjw/alcoholic) has announced the addition of the "Alcoholic Hepatitis - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Alcoholic Hepatitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Alcoholic Hepatitis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Immuron Limited - Conatus Pharmaceuticals Inc. - Intercept Pharmaceuticals, Inc. - Alfact Innovation - Generon (Shanghai) Corporation Ltd. Drug Profiles - obeticholic acid - emricasan - IMM-124E - ALF-5755 - F-652 - Oligonucleotide to Inhibit miRNA-155 for Alcoholic Liver Disease For more information visit http://www.researchandmarkets.com/research/6xxsjw/alcoholic
CNAT: 7.01 (+0.16), ICPT: 177.70 (+5.11)
Intercept misses 3Q profit forecasts
Automated Insights - Fri Nov 07, 4:04AM CST
NEW YORK (AP) _ Intercept Pharmaceuticals Inc. (ICPT) on Friday reported a third-quarter loss of $35.8 million.
ICPT: 177.70 (+5.11)
FLINT Trial in NASH Published in The Lancet
GlobeNewswire - Thu Nov 06, 6:05PM CST
-OCA meets primary endpoint with high statistical significance of p=0.0002
ICPT: 177.70 (+5.11)
Intercept Pharmaceuticals Reports Third Quarter 2014 Financial Results and Provides Business Updates
GlobeNewswire - Thu Nov 06, 4:28PM CST
Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT) (Intercept), a clinical stage biopharmaceutical company focused on the development and commercialization of novel bile acid therapeutics to treat chronic liver and intestinal diseases, today reported financial results for the quarter and nine months ended September 30, 2014 and provided other general business updates. These results are included in Intercept's Quarterly Report on Form 10-Q which has been filed with the Securities and Exchange Commission. Intercept will webcast an investor event on Monday, November 10, 2014 starting at 6:30 p.m. ET. During this webcast, management and key opinion leaders will review Intercept's development programs, including PBC and NASH.
ICPT: 177.70 (+5.11)
Will Intercept Pharmaceuticals' (ICPT) Q3 Loss Narrow? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 06, 3:02PM CST
Intercept Pharmaceuticals, Inc (ICPT) is slated to report its third-quarter 2014 results on Nov 7.
MACK: 8.63 (-0.07), MNK: 92.65 (+1.59), DNDN: 0.23 (-0.71), ICPT: 177.70 (+5.11)
Intercept to Report Third Quarter 2014 Results on November 7 and Present at Upcoming Conferences
GlobeNewswire - Fri Oct 31, 5:01AM CDT
Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT) (Intercept), a clinical stage biopharmaceutical company focused on the development and commercialization of novel bile acid therapeutics to treat chronic liver and intestinal diseases, today announced that it will report third quarter 2014 financial results before the NASDAQ Market opens on Friday, November 7, 2014. Intercept will webcast an investor event on Monday, November 10, 2014 starting at 6:30 p.m. ET. During this webcast, management and key opinion leaders will review Intercept's development programs, including its programs for PBC and NASH.
ICPT: 177.70 (+5.11)
Recognition, Product Enhancement, Marketing Approval, Upcoming Events, and Quarterly Earnings - Research Reports on Abbott, Illumina, Thermo Fisher, Intercept and Stryker
PR Newswire - Wed Oct 22, 7:40AM CDT
Today, Analysts Review released its research reports regarding Abbott Laboratories (NYSE: ABT), Illumina Inc. (NASDAQ: ILMN), Thermo Fisher Scientific, Inc. (NYSE: TMO), Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT) and Stryker Corporation (NYSE: SYK). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7389-100free.
ABT: 43.71 (+0.34), TMO: 117.06 (+0.46), ICPT: 177.70 (+5.11), ILMN: 189.51 (+3.16), SYK: 88.17 (+0.70)
Critical Alerts For Exxon Mobil, Celgene, Verizon, Intercept Pharmaceuticals and Lockheed Martin Released By InvestorsObserver
PR Newswire - Wed Oct 08, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for XOM, CELG, VZ, ICPT and LMT.
LMT: 186.92 (+0.77), ICPT: 177.70 (+5.11), XOM: 96.47 (-0.12), VZ: 50.96 (+0.10), CELG: 107.90 (+1.45)
Intercept Announces Data to be Presented at the 2014 AASLD Annual Meeting
GlobeNewswire - Wed Oct 08, 5:36AM CDT
Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat chronic liver and intestinal diseases, today announced upcoming presentations of data at the upcoming American Academy for the Study of Liver Diseases (AASLD) Annual Meeting (the Liver Meeting), being held in Boston, Massachusetts from November 7-11, 2014.
ICPT: 177.70 (+5.11)
The 5 Best Biotech Stocks in 2014...so far
Todd Campbell, The Motley Fool - Motley Fool - Fri Sep 26, 7:35AM CDT
Since the quarter is wrapping up and investors are considering their game plan heading into year-end, let's look at biotech's biggest winners for the year, why they've rallied, and whether they make sense for your portfolio . Specifically, let's...
GILD: 108.23 (+1.78), ACHN: 12.37 (+2.26), RCPT: 110.10 (+0.86), PTCT: 40.99 (+0.75), ICPT: 177.70 (+5.11), PBYI: 241.09 (+4.20)
Quarterly Changes to the NASDAQ Q-50 Index
GlobeNewswire - Mon Sep 15, 6:08AM CDT
The NASDAQ OMX Group, Inc. (Nasdaq:NDAQ) today announced the results of the quarterly re-ranking of the NASDAQ Q-50 Index (Nasdaq:NXTQ), which will become effective prior to market open on Monday, September 22, 2014.
FLEX: 10.85 (-0.01), GLNG: 51.77 (+0.74), NTES: 92.60 (+0.80), FEYE: 31.95 (+1.33), NUAN: 15.38 (+0.06), GPOR: 53.77 (-1.39), MDVN: 110.12 (-2.65), FOSL: 103.67 (+0.66), SCTY: 51.64 (+0.67), ARMH: 41.97 (+0.53), ICPT: 177.70 (+5.11), SPLK: 66.71 (-0.16), NDAQ: 43.98 (+0.10)
Intercept Pharmaceuticals Recognizes International PBC Day
GlobeNewswire - Fri Sep 12, 5:55AM CDT
Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat chronic liver and intestinal diseases, announced today its support for International Primary Biliary Cirrhosis (PBC) Day, taking place September 14, 2014.
ICPT: 177.70 (+5.11)
Global Cirrhosis Therapeutics Pipeline Review 2014 - 7 Companies & 8 Drug Profiles
M2 - Fri Sep 12, 4:03AM CDT
Research and Markets (http://www.researchandmarkets.com/research/szkbdq/cirrhosis) has announced the addition of the "Cirrhosis - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Cirrhosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cirrhosis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Gilead Sciences, Inc. - Novartis AG - Ocera Therapeutics, Inc. - Hyperion Therapeutics, Inc. - Intercept Pharmaceuticals, Inc. - PharmaIN Corporation - Alfact Innovation Drug Profiles - ornithine phenylacetate - glycerol phenylbutyrate - obeticholic acid - simtuzumab - Stem Cell Therapy for Gastrointestinal, CNS and Endocrine and Metabolic Disorders - erismodegib - ALF-5755 - PGC Based Natriuretic Peptides For more information visit http://www.researchandmarkets.com/research/szkbdq/cirrhosis
GILD: 108.23 (+1.78), OCRX: 5.65 (+0.04), ICPT: 177.70 (+5.11), NVS: 92.58 (+0.82), HPTX: 21.71 (-0.11)
